{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:58:00Z","timestamp":1772841480360,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1016\/s0169-409x(02)00023-6","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T02:36:45Z","timestamp":1034303805000},"page":"477-485","source":"Crossref","is-referenced-by-count":274,"title":["Mono-N-terminal poly(ethylene glycol)\u2013protein conjugates"],"prefix":"10.1016","volume":"54","author":[{"given":"Olaf","family":"Kinstler","sequence":"first","affiliation":[]},{"given":"Graham","family":"Molineux","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Treuheit","sequence":"additional","affiliation":[]},{"given":"David","family":"Ladd","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Gegg","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0169-409X(02)00023-6_BIB1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/11717","article-title":"Therapeutic antibody fragments with prolonged in vivo half-lives","volume":"17","author":"Chapman","year":"1999","journal-title":"Nature Biotechnol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB2","first-page":"1028","article-title":"Polyethylene glycol (PEG)-modified granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) with conserved biological activity","volume":"20","author":"Malik","year":"1992","journal-title":"Exp. Hematol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1021\/bc990148b","article-title":"Transglutaminase-mediated dual and site-specific incorporation of poly(ethylene glycol) derivatives into chimeric interleukin-2","volume":"11","author":"Sato","year":"2000","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/bc950074d","article-title":"Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins","volume":"7","author":"Gaertner","year":"1996","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/protein\/11.12.1277","article-title":"Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules","volume":"11","author":"Wang","year":"1998","journal-title":"Protein Eng."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB6","first-page":"4588","article-title":"Polyethylene glycol-modified chimeric toxin composed of transforming growth factor \u03b1 and Pseudomonas exotoxin","volume":"53","author":"Wang","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB7","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.1073\/pnas.88.16.7185","article-title":"Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol","volume":"88","author":"Hershfield","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB8","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1016\/S0021-9258(17)37331-3","article-title":"Pseudomonas exotoxin A mutants: replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner","volume":"269","author":"Kuan","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB9","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1073\/pnas.140210597","article-title":"Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity","volume":"97","author":"Tsutsumi","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB10","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1016\/S0021-9258(17)36846-1","article-title":"Pseudomonas exotoxin A mutants: replacement of surface exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner","volume":"269","author":"Benhar","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB11","series-title":"Poly(ethylene Glycol) Chemistry","year":"1992"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB12","series-title":"Poly(ethylene Glycol) Chemistry and Biological Applications","year":"1997"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB13","first-page":"326","article-title":"Laboratory synthesis of polyethylene glycol derivatives","volume":"C25","author":"Harris","year":"1985","journal-title":"Rev. Macromol. Chem. Phys."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/bc00032a002","article-title":"Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates","volume":"6","author":"Zalipsky","year":"1995","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40-kDa branched polyethylene glycol-conjugated interferon \u03b1-2a for the treatment of hepatitis C","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.2326644","article-title":"PEG-treated enzymes are nearly invisible to the immune system","volume":"248","author":"Pool","year":"1990","journal-title":"Science"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB17","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/bc990076o","article-title":"Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds","volume":"10","author":"Lee","year":"1999","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB18","article-title":"Site protected PEGylation of recombinant tumor necrosis factor receptor","author":"Pettit","year":"1997"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/bc00034a007","article-title":"Synthesis and physiochemical properties of protein conjugates with water-soluble poly(alkylene oxides)","volume":"6","author":"Topchieva","year":"1995","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB20","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2141.1992.tb06940.x","article-title":"Polyethylene glycol (PEG) modification of granulocyte\u2013macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity","volume":"82","author":"Knusli","year":"1992","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF01024656","article-title":"Improvement of oxygen-carrying properties of human hemoglobin by chemical modification with a benzene hexacarboxylate-monosubstituted polyoxyethylene","volume":"10","author":"Dellacherie","year":"1991","journal-title":"J. Protein Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB22","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1074\/jbc.272.4.2312","article-title":"Structure\u2013function studies of interleukin 15 using site-specific mutagenesis, polyethylene glycol conjugation and homology modeling","volume":"272","author":"Pettit","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB23","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1073\/pnas.91.26.12544","article-title":"Subtiligase: a tool for semisynthesis of proteins","volume":"91","author":"Chang","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/bc00002a005","article-title":"A general method for highly selective crosslinking of unprotected polypeptides via pH-controlled modification of N-terminal \u03b1-amino groups","volume":"1","author":"Wetzel","year":"1990","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nbt0490-343","article-title":"Site-directed PEGylation of recombinant interleukin-2 at its glycosylation site","volume":"8","author":"Goodson","year":"1990","journal-title":"Bio\/Technology"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0076-6879(87)38037-1","article-title":"Labeling glycoconjugates with hydrazide reagents","volume":"138","author":"Wilchek","year":"1987","journal-title":"Methods Enzymol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/abio.1995.1511","article-title":"Studies on the rate and control of antibody oxidation by periodate","volume":"231","author":"Wolfe","year":"1995","journal-title":"Anal. Biochem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB28","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.4049\/jimmunol.154.11.5919","article-title":"Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments","volume":"154","author":"Leung","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB29","unstructured":"G.P. Royer, Modifying enzymes with polyethylene glycol and product produced thereby (1977) US Patent 4002531, Pierce Chemical."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB30","unstructured":"J.M. Harris, M.R. Sedaghat-Herati, Preparation and use of polyethylene glycol propionaldehyde (1993) US patent 5252714, University of Alabama, Huntsville."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/bc00026a005","article-title":"Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation","volume":"5","author":"Chamow","year":"1994","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01024842","article-title":"Reductive alkylation of proteins","volume":"3","author":"Means","year":"1984","journal-title":"J. Prot. Chem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB33","series-title":"Chemistry of Protein Conjugation and Cross-linking","first-page":"13","article-title":"Reactive groups of proteins and their modifying agents","author":"Wong","year":"1991"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB34","unstructured":"O.B. Kinstler, N.E. Gabriel, C.E. Farrar, R.B. DePrince, N-Terminally chemically modified protein compositions and methods. (1999) US Patent US 5985265, Amgen."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB35","unstructured":"O.B. Kinstler, Q. Yan, BDNF and NT-3 polypetides selectively linked to polyethylene glycol. (1998) US Patent US 5770577, Amgen."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB36","unstructured":"T.D. Bartley, J.M. Bogenberger, R.A. Bosselman, P. Hunt, O.B. Kinstler, B.B. Samal, Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation. (1998) US Patent US 5795569, Amgen."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB37","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): The first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1023\/A:1016042220817","article-title":"Characterization and stability of N-terminally pegylated Rhg-CSF","volume":"13","author":"Kinstler","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB39","first-page":"69","article-title":"New sustained-duration form of neupogen","author":"Kinstler","year":"2000"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB40","article-title":"Filgrastim (r-metHuG-CSF) in clinical practice","author":"Morstyn","year":"1998"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB41","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB42","first-page":"3710","article-title":"Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats","volume":"51","author":"Tanaka","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB43","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.45.7.1947-1951.2001","article-title":"Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients","volume":"45","author":"Fukuda","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB44","first-page":"199","article-title":"Pharmacokinetics (PK) of human granulocyte colony stimulating factor (G-CSF) in patients with neutropenia using a mixed effects model","volume":"55","author":"Sambol","year":"1994","journal-title":"Clin. Pharmacol. Therapeut."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB45","first-page":"6615","article-title":"Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rats","volume":"50","author":"Tanaka","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB46","first-page":"507a","article-title":"Cytokinetic model of rmethHuG-CSF\u2013SD\/01 (SD\/01) mediated granulopoiesis and the \u2018self-regulation\u2019 of SD\/01 elimination in non-small cell lung cancer (NSCLC)","volume":"92","author":"Roskos","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB47","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2000.18.13.2522","article-title":"Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy","volume":"18","author":"Johnston","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000205503","article-title":"Demonstration and some properties of human thrombopoietin in thrombocythemic sera","volume":"20","author":"Keleman","year":"1958","journal-title":"Acta Haematol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/369565a0","article-title":"Cloning and expression of murine thrombopoietin cDNA and stimulation of platlet production in vivo","volume":"369","author":"Lok","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/oxfordjournals.jbchem.a124883","article-title":"Purification and characterization of thrombopoietin","volume":"118","author":"Kato","year":"1995","journal-title":"J. Biochem."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"deSauvage","year":"1994","journal-title":"Nature"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB52","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platlet production","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood.V86.2.540.bloodjournal862540","article-title":"Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor","volume":"86","author":"Hunt","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB55","first-page":"368A","article-title":"Regulation of TPO mRNA expression and protein production TPO gene regulation appears post transcriptional, and endogenous levels are inversely correlated to megakaryocyte mass and circulating platlet count","volume":"86","author":"Chang","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2141.1967.tb08753.x","article-title":"Regulation of platlet production \u2018Hypersplenism\u2019 in the experimental animal","volume":"13","author":"De-Gabriele","year":"1967","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/08977190009003246","article-title":"Pharmacokinetic analysis of Pegylated megakaryocyte growth and development factor in humans","volume":"18","author":"De-Boer","year":"2000","journal-title":"Growth Factors"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB58","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1023\/A:1011945704248","article-title":"PEGylation prevents the N-terminal degradation of megakaryocyte growth and development factor","volume":"15","author":"Guerra","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/S0169-409X(02)00023-6_BIB59","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V86.12.4486.bloodjournal86124486","article-title":"Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice","volume":"86","author":"Hokom","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB60","first-page":"690A","article-title":"The acute effect of Pegylated recombinant human growth and development factor (PEG\u2013MGDF) on platlet counts in normal and splenectomized Sprague\u2013Dawley rats after a single intravenous dose","volume":"86","author":"Coleman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB61","first-page":"353A","article-title":"The prolonged hematologic effects of a single injection of PEG\u2013rHuMGDF in normal and thrombocytopenic mice","volume":"88","author":"Ulich","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB62","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.V95.8.2514","article-title":"Effects of megakaryocyte growth and development factor on platlet production, platlet life span, and platlet function in healthy human volunteers","volume":"95","author":"Harker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0169-409X(02)00023-6_BIB63","series-title":"Thrombopoiesis and Thrombopoietins","first-page":"203","article-title":"The biological significance of truncated and full-length forms of mp1 ligand","author":"Foster","year":"1997"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X02000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X02000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T16:21:24Z","timestamp":1681834884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X02000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S0169409X02000236"],"URL":"https:\/\/doi.org\/10.1016\/s0169-409x(02)00023-6","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}